IRIDEX CORP(IRIX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,679 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
IRIX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for IRIDEX CORP (IRIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRIX at 25.0/100 on a 32-signal composite quality model, placing it at rank #2,679 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (9.0) and revenue scale (9.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 46.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRIDEX CORP reports quarterly revenue of $12.6M, net income of $-1.3M, an operating margin of -8.2%. Top institutional holders of IRIX by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, MORGAN STANLEY, based on the most recent SEC filings. IRIX trades on the Nasdaq exchange and files with the SEC under CIK 1006045. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRIDEX CORP directly from SEC EDGAR. IRIDEX CORP's 13F Pro composite quality score has ranged between 15 and 39 since 2021, currently 25.0 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$12.6M
Net Income
Q2 2026
$-1.3M
Free Cash Flow
Q2 2026
$124.0K
Operating Margin
Q2 2026
-8.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+8.2% YoYNet Income
+50.2% YoYOperating Income
+69.0% YoYEPS (Diluted)
+51.9% YoYTotal Assets
+0.1% YoYTotal Debt
Op. Cash Flow
+71.0% YoYFree Cash Flow
+69.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $52.7M +8.2% | $48.7M -6.2% | $51.9M -9.0% | $57.0M +5.7% | $53.9M +48.3% | $36.3M |
| Net Income | $-4.4M +50.2% | $-8.9M +6.9% | $-9.6M -26.8% | $-7.5M -44.4% | $-5.2M +17.4% | $-6.3M |
| Operating Income | $-2.6M +69.0% | $-8.3M +17.0% | $-10.0M -32.7% | $-7.5M -0.1% | $-7.5M -14.4% | $-6.6M |
| EPS (Diluted) | $-0.26 +51.9% | $-0.54 +8.5% | $-0.59 -25.5% | $-0.47 -38.2% | $-0.34 +26.1% | $-0.46 |
| Total Assets | $29.2M +0.1% | $29.1M -15.4% | $34.4M -18.6% | $42.3M -13.1% | $48.7M +74.1% | $28.0M |
| Total Debt | — | $2.7M | — | — | — | $2.5M |
| Operating Cash Flow | $-2.1M +71.0% | $-7.3M -8.0% | $-6.7M +29.1% | $-9.5M -215.8% | $8.2M +353.8% | $-3.2M |
| Free Cash Flow | $-2.3M +69.1% | $-7.3M -6.5% | $-6.9M +30.1% | $-9.8M -222.5% | $8.0M +340.1% | $-3.3M |
Get alerted when IRIX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IRIDEX CORP including:
Top Institutional Holders of IRIX
VANGUARD CAPITAL MANAGEMENT LLC
$589.2K514,593 shRENAISSANCE TECHNOLOGIES LLC
$485.0K423,542 shMORGAN STANLEY
$349.4K305,193 shWEBER CAPITAL MANAGEMENT LLC /ADV
$206.6K180,451 shGEODE CAPITAL MANAGEMENT, LLC
$159.2K138,960 shCITADEL ADVISORS LLC
$113.3K98,950 shPERKINS CAPITAL MANAGEMENT INC
$81.1K70,800 shVANGUARD FIDUCIARY TRUST CO
$68.9K60,155 shSTATE STREET CORP
$51.2K44,718 shGOLDMAN SACHS GROUP INC
$46.3K40,454 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $589.2K | 514,593 |
| RENAISSANCE TECHNOLOGIES LLC | $485.0K | 423,542 |
| MORGAN STANLEY | $349.4K | 305,193 |
| WEBER CAPITAL MANAGEMENT LLC /ADV | $206.6K | 180,451 |
| GEODE CAPITAL MANAGEMENT, LLC | $159.2K | 138,960 |
| CITADEL ADVISORS LLC | $113.3K | 98,950 |
| PERKINS CAPITAL MANAGEMENT INC | $81.1K | 70,800 |
| VANGUARD FIDUCIARY TRUST CO | $68.9K | 60,155 |
| STATE STREET CORP | $51.2K | 44,718 |
| GOLDMAN SACHS GROUP INC | $46.3K | 40,454 |
Companies Similar to IRIX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ACCURAY INC
ANGIODYNAMICS INC
TREACE MEDICAL CONCEPTS, INC.
SunOpta Inc.
BIODESIX INC
TELA Bio, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put IRIX on your watchlist
Track score changes the day IRIDEX CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IRIX a good stock to buy?
13F Pro's AI-powered analysis of IRIDEX CORP (IRIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRIX are available on the IRIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IRIX is classified as a small company.
Which hedge funds own IRIX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IRIDEX CORP's investment landscape.